Skip to main content

Advertisement

SpringerLink
Log in

Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Clinical role of low-dose aspirin (LDA) in pathogenesis of gastroesophageal reflux disease is by far controversial. This can be attributed to the paucity of basic research detailing the mechanism of LDA-induced esophageal mucosal injury (EI) on underlying chronic acid reflux esophagitis (RE).

Aim

The aim of this study was to clarify the effect of LDA on chronic RE in rats.

Methods

Esophagitis was induced in 8-week-old male Wistar rats by ligating the border between forestomach and glandular portion with a 2–0 silk tie and covering the duodenum with a small piece of 18-Fr Nélaton catheter. Seventy-eight chronic RE rat models were divided into five treatment groups, consisting of orally administered vehicle (controls), and aspirin doses of 2, 5, 50 or 100 mg/kg once daily for 28 days. EI was assessed by gross area of macroscopic mucosal injury, severity grade of esophagitis and microscopic depth of infiltration by inflammatory cells.

Results

Area of esophagitis in animals with aspirin dose of 100 mg/kg/day showed a 36.5% increase compared with controls, although it failed to achieve statistical significance (p = 0.812). Additionally, the rate of severe EI was increased in animals with aspirin dose of 100 mg/kg/day as compared with controls (p < 0.05). The grade of severity correlated with the depth of inflammation (r s = 0.492, p < 0.001).

Conclusions

Maximal dose aspirin (100 mg/kg/day) contributed in exacerbating preexisting EI. LDA (2 and 5 mg/kg/day), on the other hand, did not affect chronic RE in this model. LDA seems to be safe for use in patients with chronic RE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920.

    Article  PubMed  Google Scholar 

  2. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in Japanese population. J Gastroenterol. 2009;44:518–534.

    Article  PubMed  Google Scholar 

  3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.

    Article  PubMed  Google Scholar 

  4. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369:614.

    Article  PubMed  Google Scholar 

  5. Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol. 2009;44:544–549.

    Article  CAS  PubMed  Google Scholar 

  6. Shimada Y, Nagahara A, Hojo M, et al. Upper gastrointestinal mucosal injury and symptoms in elderly low-dose aspirin users. Gastroenterol Res Pract. 2015. https://doi.org/10.1155/2015/252963.

    Google Scholar 

  7. Taha AS, Angerson WJ, Morran CG. Correlation between erosive oesophagitis and gastro-duodenal disease: the influence of aspirin, simple analgesics, and Helicobacter pylori. Eur J Gastroenterol Hepatol. 2002;14:1313–1317.

    Article  CAS  PubMed  Google Scholar 

  8. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–2473.

    Article  CAS  PubMed  Google Scholar 

  9. Yamamoto T, Mishina Y, Ebato T, et al. Prevalence of erosive esophagitis among Japanese patients taking low-dose aspirin. J Gastroenterol Hepatol. 2010;25:792–794.

    Article  CAS  PubMed  Google Scholar 

  10. Omura N, Kashiwagi H, Chen G, Suzuki Y, Yano F, Aoki T. Establishment of surgically induced chronic acid reflux esophagitis in rats. Scand J Gastroenterol. 1999;34:948–953.

    Article  CAS  PubMed  Google Scholar 

  11. Miwa H, Koseki J, Oshima T, et al. Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa. J Gastroenterol. 2010;45:478–487.

    Article  PubMed  Google Scholar 

  12. Nahata M, Saegusa Y, Harada Y, Tsuchiya N, Hattori T, Takeda H. Changes in ghrelin-related factors in gastroesophageal reflux disease in rats. Gastroenterol Res Pract. 2013. https://doi.org/10.1155/2013/504816.

    PubMed  PubMed Central  Google Scholar 

  13. Masaka T, Iijima K, Endo H, et al. Gender differences in oesophageal mucosal injury in a reflux oesophagitis model of rats. Gut. 2013;62:6–14.

    Article  CAS  PubMed  Google Scholar 

  14. Abdel-Aziz H, Schneider M, Neuhuber W, et al. GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis. Mol Med. 2015;21:1011–1024.

    Article  CAS  Google Scholar 

  15. Lee J, Anggiansah A, Anggiansah R, Young A, Wong T, Fox M. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007;5:1392–1398.

    Article  PubMed  Google Scholar 

  16. Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5:439–444.

    Article  PubMed  Google Scholar 

  17. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211.

    Article  PubMed  Google Scholar 

  18. Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25:1195–1205.

    CAS  PubMed  Google Scholar 

  19. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119–125.

    Article  CAS  PubMed  Google Scholar 

  20. Masuda T, Mittal SK. Current animal models of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. J Nat Sci. 2017;3:e387.

    Google Scholar 

  21. Lanas AI, Sousa FL, Ortego J, et al. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol. 1995;7:1065–1072.

    Article  CAS  PubMed  Google Scholar 

  22. Pawlik M, Pajdo R, Kwiecien S, et al. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. J Physiol Pharmacol. 2011;62:75–86.

    CAS  PubMed  Google Scholar 

  23. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol. 2005;56:5–31.

    Google Scholar 

  24. Sostres C, Gargallo CJ. Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26:141–151.

    Article  CAS  PubMed  Google Scholar 

  25. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88:1547–1565.

    Article  CAS  PubMed  Google Scholar 

  26. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17–25.

    Article  CAS  PubMed  Google Scholar 

  27. Lanas A, Jiménez P, Ferrández A, et al. Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis. Inflammation. 2003;27:21–29.

    Article  CAS  PubMed  Google Scholar 

  28. Fujiwara Y, Higuchi K, Hamaguchi M, et al. Increased expression of transforming growth factor-alpha and epidermal growth factor receptors in rat chronic reflux esophagitis. J Gastroenterol Hepatol. 2004;19:521–527.

    Article  CAS  PubMed  Google Scholar 

  29. Edebo A, Vieth M, Tam W, et al. Circumferential and axial distribution of esophageal mucosal damage in reflux disease. Dis Esophagus. 2007;20:232–238.

    Article  CAS  PubMed  Google Scholar 

  30. Nishino M, Sugimoto M, Kodaira C, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010;55:1627–1636. https://doi.org/10.1007/s10620-009-0920-3.

    Article  CAS  PubMed  Google Scholar 

  31. Nishino M, Sugimoto M, Kodaira C, et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol. 2011;51:1079–1086.

    Article  CAS  PubMed  Google Scholar 

  32. Uotani T, Sugimoto M, Nishino M, et al. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol. 2012;10:879.e2–885.e2.

    Article  Google Scholar 

Download references

Acknowledgments

This study was technically supported in part by Department of Pathology, the Jikei University School of Medicine.

Author information

Authors and Affiliations

  1. Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan

    Takahiro Masuda, Fumiaki Yano, Nobuo Omura, Kazuto Tsuboi, Masato Hoshino, Se Ryung Yamamoto, Shunsuke Akimoto, Hideyuki Kashiwagi & Katsuhiko Yanaga

Authors
  1. Takahiro Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumiaki Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuo Omura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuto Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masato Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Se Ryung Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shunsuke Akimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideyuki Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuhiko Yanaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Masuda.

Ethics declarations

Conflict of interest

All authors have read the journal publication policy and have no relevant financial disclosures and conflicts of interest with regards to this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masuda, T., Yano, F., Omura, N. et al. Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats. Dig Dis Sci 63, 72–80 (2018). https://doi.org/10.1007/s10620-017-4840-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4840-3

Keywords

Search

Navigation